New research findings were reported today from the ENZA-p study (ANZUP 1901), led by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) in collaboration between ANZUP, the NHMRC Clinical Trials Centre at the University of Sydney and the Australasian Radiopharmaceutical Trials Network. The findings reveal that a world-first combination treatment approach improve both survival and quality of life, compared to the standard of care therapy for people with metastatic castration-resistant prostate cancer (mCRPC).
Lutetium-PSMA (LuPSMA) is a treatment that can precisely target prostate cancer cells in the body with a radioactive substance that can kill those cells. ENZA-p is a world-first clinical trial to test the combination of LuPSMA with a standard best practice hormonal treatment (enzalutamide), and was specifically designed to try to help people who might have been less likely to benefit from enzalutamide. The trial also tested an innovative world-first treatment approach called ‘adaptive dosing,’ which uses imaging and blood results to identify patients who are responding to the treatment and determine those patients who were most likely to benefit from continued treatment, tailoring the treatment approach for each patient. Results from ENZA-p were published in The Lancet Oncology and presented at today’s American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium in San Francisco.
Professor Louise Emmett, ENZA-p Study Chair and Director of Theranostics and Nuclear Medicine at St Vincent’s says, “We are excited to present the positive results of our ENZA-p study internationally.
“Our findings show that participants who received the new treatment combination experienced longer and better lives in terms of increased overall survival and improved pain and fatigue for those with an otherwise poor prognosis.
“The study opens the door for exploring this combination of treatments earlier in metastatic prostate cancer.”
Those living with mCRPC have approximately a 3 in 10 chance of surviving 5 years. Currently, there are very few options to treat mCRPC.
Australian and New Zealand Urogenital and Prostate Cancer Trials Group CEO, Samantha Oakes says, “Our mission at ANZUP is to improve the lives of people affected by bladder, kidney, testicular, penile and prostate cancers, as the leading non-for-profit research charity funding multidisciplinary collaborative clinical trials for these ‘Below the Belt’ cancers. Since our inception in 2008, ANZUP has funded 33 Below the Belt cancer trials across 772 global sites providing over 8,000 participants access to innovative clinical trials.”
“We are proud to showcase our Australian-led first-of-its-kind research on an international stage. The discoveries through the ENZA-p study will pave the way for more effective combination therapies that can improve survival outcomes and revolutionise care for people with advanced prostate cancer with poor prognosis.”
ENZA-p is an investigator-initiated trial led by ANZUP in partnership with the Prostate Cancer Research Alliance (PCRA), a joint initiative between the Australian Government and Movember.
The full research results will be presented at The American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium from February 13–15, 2025 at the Moscone West Conference Center in San Francisco, California, USA.
Source: ANZUP
